Omiloxetine

Omiloxetine (omiloextinum, omiloxetino INN)[1]:212213 was a selective serotonin reuptake inhibitor drug candidate that underwent preclinical development by the Spanish pharmaceutical company, Ferrer Internacional, until 2005, when it was abandoned.[2][3]

Omiloxetine
Clinical data
ATC code
  • None
Identifiers
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC27H25F2NO4
Molar mass465.497 g·mol−1
3D model (JSmol)
Density1.3±0.1 g/cm3
Melting point228.65 °C (443.57 °F)
Boiling point587.2 °C (1,089.0 °F)
Solubility in water0.0015 mg/mL (20 °C)

References

  1. WHO Drug Information, Vol. 10, No. 4, 1996 Proposed INN: List 76
  2. Terencio, Jose (2005-12-05). "Omiloxetine - Ferrer licensing offer, worldwide". R & D Focus Drug News. Archived from the original on 2016-03-07. Retrieved 2012-05-19.
  3. De Lecea, Dr Carlos (2003-12-08). "Omiloxetine - Ferrer partnering opportunity, worldwide Ferrer preclinical data". R & D Focus Drug News. Archived from the original on 2016-03-07. Retrieved 2012-05-19.


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.